Humira

© GettyImages/ardaguldogan

FDA reviewing higher dose Hyrimoz biosimilar

By Jane Byrne

The US FDA has accepted a supplemental biologics license application (sBLA) from Sandoz for a high concentration formulation of 100 mg/mL (HCF) of its biosimilar, Hyrimoz.

(Image: Getty/Evgeny_D)

FDA approves the entrance of two biosimilars

By Ben Hargreaves

US FDA gives approval to Samsung Bioepis’ Humira biosimilar and Pfizer’s Rituxan biosimilar, as the number of such medicines gaining entry onto the US market steadily increases.

(Image: Getty/Utah778)

AbbVie shares fall as Humira lawsuit ramps up

By Maggie Lynch

The California Department of Insurance has sued AbbVie for allegedly providing monetary gifts to health-care providers for prescribing its biologic, Humira.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers